Cycloheximide reduces infarct volume when administered up to 6 h after mild focal ischemia in rats

Brain Res. 2001 Nov 2;917(2):147-57. doi: 10.1016/s0006-8993(01)02822-0.

Abstract

We have previously described a rodent model of brief (30 min) middle cerebral artery occlusion followed by reperfusion, in which infarction develops gradually, reaching completion more than 3 days after ischemia, accompanied by morphological, biochemical, and pharmacological evidence of apoptosis. In the present study, we tested the hypotheses that delayed administration of a protein synthesis inhibitor would be effective in reducing tissue injury in this slowly evolving ischemic infarction, and that efficacy of this treatment would wane with more prolonged ischemia. Focal cerebral ischemia was induced in Long-Evans rats by occlusion of the right middle cerebral artery. Infarction volume was analyzed using triphenyl tetrazolium chloride staining, and morphology was studied using hematoxylin and eosin stained sections. Following 30 min middle cerebral artery occlusion and reperfusion, the core ischemic region exhibited vacuolization in the neuropil by 36 h after ischemia, and infarction reached full size by 7 days after ischemia. Cycloheximide reduced infarct volume when given up to 6 h after ischemia. If the duration of ischemic insult was increased to 90 min, the therapeutic window for delayed cycloheximide was only 30 min. In permanent middle cerebral artery occlusion, cycloheximide was ineffective even when given prior to ischemia onset. After mild, but not severe, ischemic insults, cerebral infarction develops slowly and may be treatable with protein synthesis inhibitors, even when treatment is delayed for up to 6 h after the onset of ischemia.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Brain Ischemia / drug therapy*
  • Cerebral Infarction / pathology*
  • Cycloheximide / administration & dosage*
  • Cycloheximide / therapeutic use
  • Drug Administration Schedule
  • Male
  • Protein Synthesis Inhibitors / administration & dosage*
  • Protein Synthesis Inhibitors / therapeutic use
  • Rats
  • Rats, Long-Evans

Substances

  • Protein Synthesis Inhibitors
  • Cycloheximide